The FDA database recorded a supplement to new drug application 217806, Eli Lilly's tirzepatide marketed as Zepbound, harvested on 24 September 2026. The record does not state what the supplement concerns — it may relate to labelling, manufacturing, a new presentation or an indication, and the harvest carries no detail.
Without the approval letter or revised label, no change in prescribing follows. Readers who prescribe tirzepatide should check the updated FDA label when it is posted rather than rely on this notice.
Zepbound is the brand used in the US for weight management; the regulatory position in India is separate and this record does not change it.
- No change to tirzepatide prescribing follows from this record alone
- Check the updated FDA label for what the supplement changes
- Treat a supplement as potentially administrative until the label says otherwise
- The US record does not change CDSCO's position in India
Why it matters
Supplements to high-profile drugs often precede label changes, so this is one to watch rather than act on.
Don't overread it
A supplement record is not a new indication or a safety finding, and its content is not yet known.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free